14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NVS vs JNJ: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Johnson & Johnson (JNJ) captures the overall head-to-head institutional edge over Novartis AG (NVS) on higher Unified Composite conviction (43.8/100 HOLD vs. 41.5/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while NVS wins 3–2 across the 6-pillar growth and valuation breakdown. NVS trades at $161.59 (16.2x Forward P/E, 34.0% operating margin) versus JNJ at $284.71 (24.6x Forward P/E, 26.6% operating margin).
Growth vs. Quality Trade-Off: JNJ earns the overall head-to-head edge with a stronger Unified Composite Score (43.8/100 HOLD vs. NVS 41.5/100 SELL) and -0.06β · 25% Vol risk profile, whereas NVS leads top-line expansion (+4.7% YoY revenue growth, 3.81x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs JNJ. Trailing 12-month operating profitability (NVS 34.0% vs JNJ 26.6%) and valuation multiples (NVS 16.2x vs JNJ 24.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment41.2% of Rev ($16.7B)
90D Engineering Disclosures0 Published
JNJ Moat ProfileScale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $682.5B market capitalization and 26.6% operating margin.
OpEx & R&D Reinvestment41.2% of Rev ($40.9B)
90D Engineering Disclosures0 Published
Investor FAQ NVS vs JNJ Key Questions & Quantitative Answers
As of Nov 16, 2026, Johnson & Johnson (JNJ) captures the overall head-to-head institutional edge over Novartis AG (NVS) on higher Unified Composite conviction (43.8/100 HOLD vs. 41.5/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while NVS wins 3–2 across the 6-pillar growth and valuation breakdown. NVS trades at $161.59 (16.2x Forward P/E, 34.0% operating margin) versus JNJ at $284.71 (24.6x Forward P/E, 26.6% operating margin). Growth vs. Quality Trade-Off: JNJ earns the overall head-to-head edge with a stronger Unified Composite Score (43.8/100 HOLD vs. NVS 41.5/100 SELL) and -0.06β · 25% Vol risk profile, whereas NVS leads top-line expansion (+4.7% YoY revenue growth, 3.81x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
JNJ leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with JNJ at +5.9% YoY revenue growth and -95.9% YoY earnings growth on $99.3B TTM revenue (67.8% gross margin, 26.6% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $99.3B for JNJ. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 41.2% of Rev ($40.9B) (0 disclosures) for JNJ.
NVS screens cheaper on headline valuation multiples. NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas JNJ trades at 24.6x Forward P/E, 43.0x Trailing P/E, 3.16x PEG, and 7.2x EV/Revenue (19.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus JNJ (20.0% ROE) capital efficiency.
In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk). By comparison, JNJ carries 25.7% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.76x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.06β · 25% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.